** Brokerage Jefferies raises PT on drug developer Xenon Pharmaceuticals XENE.O to $65 from $60; maintains "buy" rating
** New PT represents a 62% upside to the stock's last close
** Brokerage says it sees a "catalyst-rich period" ahead for XENE, driven by multiple late-stage trials of co's experimental drug XEN1101 targeting epilepsy and depression
** Brokerage says XENE is on track to report data from the first of its two ongoing late-stage trials of XEN1101 in H2 this year, which could result in a "15-35% stock move"
** Brokerage places probability of success at between 80% and potentially higher than 85% for the trial
** XENE fell 12.7% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。